Robotic Surgery for Prostate Cancer: There are three main objectives that must be discussed and followed during your recovery. These are coined the term “trifecta” and include:

  • Oncological (Cancer-Related) cure
  • Return of urinary control (Continence)
  • Recovery of sexual function (Potency)

Prostate cancer recurrence is highly related to several pre-operative and post-surgical pathology parameters. These include:

  • Pre-operative PSA level
  • Pathology final: Gleason score
  • Pathologic stage (capsular involvement and seminal vesicle involvement)
  • Margin status

A thorough discussion of these details will take place after the final histo-pathological report is available.

After complete removal of the prostate and accessory organs, the PSA level should decrease to an undetectable (<0.02 ng/mL) level within four to six weeks of surgery.

If the prostate cancer has been completely eradicated, the PSA should remain negligible for the rest of your life. If there were to be a recurrence of disease, the PSA would become detectable on the blood test.

As such, following radical prostatectomy, you will be evaluated in the uro-oncology clinic every three months for the upcoming year and every six months the second year after surgery.

If the PSA remains negligible and there are no high risk pathological features (such as extracapsular extension of the tumor, invasion of cancer into the seminal vesicles or lymph nodes, or positive surgical margins), a yearly PSA would be recommended.

In the event of high risk pathologic features, your case will likely be presented at the weekly inter-disciplinary uro-oncology rounds to discuss the need for additional therapy.